Identification of PAthways of Kinase Inhibitors TOxicity
Sponsored by Groupe Hospitalier Pitie-Salpetriere
About this trial
Last updated 7 years ago
Study ID
CIC1421-1906
Status
Completed
Type
Observational
Placebo
No
Accepting
All Ages
All Sexes
Trial Timing
Ended 7 years ago
What is this trial about?
The investigators are identifying clinical diagnoses and toxicities associated with kinase inhibitors prescription. This identification will be applied will be applied in an electronic-health-record (EHR) cohort including North American and European.
What are the participation requirements?
Inclusion Criteria
* Patient treated with a kinase inhibitor
* Patient identified in the VUMC EHR cohort or having a toxicity reported in the VigiBase
Exclusion Criteria
-